Nancy K. Valente, M.D., serves as the Chief Development Officer at XENCOR, INC., where she plays a pivotal role in steering the company's clinical and product development strategies. With a robust background in medicine and pharmaceutical development, Dr. Valente brings extensive expertise to her position. She earned her M.D. from a prestigious medical school and has since accumulated over two decades of experience in the biopharmaceutical industry. Her career has been marked by significant contributions to the development of novel therapies, particularly in the fields of oncology and immunology. Prior to joining XENCOR, Dr. Valente held several key leadership positions at major pharmaceutical companies, where she was instrumental in advancing multiple drug candidates from early-stage research through to regulatory approval and commercialization. Her strategic vision and deep understanding of clinical development have been crucial in driving successful outcomes for various therapeutic programs. At XENCOR, she oversees the development of the company’s innovative pipeline of engineered antibodies and cytokines, ensuring that these potential treatments meet rigorous scientific and regulatory standards. Dr. Valente's achievements extend beyond her corporate roles; she is also an active member of several professional organizations dedicated to advancing medical research and patient care. Her commitment to improving patient outcomes is evident in her work at XENCOR, where she leads efforts to bring transformative therapies to market. Under her guidance, XENCOR continues to push the boundaries of what is possible in the treatment of serious diseases, solidifying its position as a leader in the biopharmaceutical industry.